Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

CAMP4 Therapeutics (NASDAQ:CAMP) priced its IPO of 6.82M shares at an initial public offering price of $11.00 per share. The gross proceeds are expected to be ~$75M. CAMP4’s common stock is expected ...

Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression ...

CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering.

CAMP4 Therapeutics Corporation CAMP IPO will take place October, 11 on the NASDAQ exchange under the ticker CAMP. The company ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...

CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting ...

Camp4 Therapeutics is seeking $75 million in its IPO to advance clinical-stage programs. Learn more about CAMP stock and ...

CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics ...